As previously reported, Evercore ISI analyst Josh Schimmer upgraded Bluebird Bio (BLUE) to Outperform from In Line, stating that its recent updates for LentiGlobin for sickle cell disease and for its myeloma CAR-T program partnered with Celgene (CELG) have increased his view of the prospects for commercial success for both programs. While competitor CAR-T updates may show that bb2121 is not particularly differentiated, it will have a key first-mover advantage and strong commercial partner, Schimmer tells investors. Schimmer raised his price target on Bluebird shares to $230 from $175.